Eagle Pharmaceuticals announced that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories. Eagle had asserted its Orange Book-listed patents against Dr. Reddy’s related to its new drug application referencing BENDEKA. Under the settlement agreement, Dr. Reddy’s has the right to market its product beginning November 17, 2027, or earlier based on certain circumstances. The settlement agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The settlement with Dr. Reddy’s follows Eagle’s previously announced settlements with Hospira and Accord Healthcare related to their new drug applications referencing BENDEKA.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EGRX:
- Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)
- Eagle Pharmaceuticals price target lowered to $31 from $41 at Piper Sandler
- Eagle Pharmaceuticals sees 2023 adjusted EPS $4.20-$4.53, consensus $4.49
- Eagle Pharmaceuticals reports Q4 adjusted EPS $1.10, consensus 83c
- Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
